Epigenetics Drugs and Diagnostic Technologies Market by Product Type, by Application, by Geography – Forecast to 2028


Report - ID613011 | 10 July, 2019 | Healthcare | 100 pages | Report Type (Global) | Publisher Name - RFM

Market Analysis Insights 
The epigenetics drugs and diagnostic technologies market is expected to grow globally with an estimated CAGR 20.2% to reach USD 6.29 billion by 2028.  Increasing prevalence of target diseases, growing global geriatric population and increasing collaborations between biotechnology companies, pharmaceutical companies and academic research institutes are the main market drivers of this market.

 Market Segment
The Market is segmented based on Product
• Reagents
• Kits
o ChIP Sequencing Kit
o Whole Genomic Amplification Kit
o Bisulfite Conversion Kit
o RNA Sequencing Kit
o Others
• Instruments
• Enzymes
• Services

The Market is segmented based on Technology
• DNA Methylation
• Histone Methylation
• Histone Acetylation
• Large Non-coding RNA
• MicroRNA Modification
• Chromatin Structures

The Market is segmented based on Application
• Oncology
o Solid Tumors
o Liquid Tumors
• Non-oncology
o Inflammatory Diseases
o Metabolic Diseases
o Infectious Diseases
o Cardiovascular Diseases


The Market is segmented based on Type of Therapy
• Histone Deacetylase (HDAC) Inhibitors
• DNA Methyltransferase (DNMT) Inhibitors

The above segmentation is covered for all countries and regions listed below
• North and South America
o U.S.
o Canada
o Mexico
o Brazil
o Rest of Americas
• Europe
o Germany
o France
o U.K.
o Italy 
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o Rest of APAC
• Middle East and Africa
Competitive Research
The major players in the epigenetics drugs and diagnostic technologies market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Eisai Co., Ltd., Novartis AG, Illumina, Inc., Merck & Co., Qiagen,  Abcam plc., Astex Pharmaceuticals, Oncolys BioPharma Inc., Spectrum Pharmaceuticals, Inc. ¸Syndax
Leave a Message